A randomized clinical trial evaluating the effect of empagliflozin on triglycerides in obese adults: Role of visceral fat.

ABSTRACT:

Background

Empagliflozin, a sodium glucose cotransporter 2 inhibitor, is a medication to treat type 2 diabetes. The effect of empagliflozin in persons without diabetes has received less attention. Here we conducted a randomized, double-blind placebo-controlled clinical trial to examine the effect of empagliflozin on plasma triglycerides in obese non-diabetic adults.

Methods

Participants (n = 35; BMI ≥ 30 kg/m²) underwent body composition assessments using MRI, and were randomly assigned to either placebo or empagliflozin (10 mg/d) for three months. At the baseline and post-treatment visit, after an overnight fast, blood was drawn for biochemical analysis. Participants received [U-¹³C₃]glycerol orally followed by multiple blood draws over 3 h

SUBMITTER: Lee MH 

PROVIDER: S-EPMC8728102 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature